Exact Sciences preliminary Q4 revenues rise 16%

Exact Sciences reportedly expects to report revenues of $550.7–$552.7 million for the fourth quarter, a 16% increase compared to the prior-year period and a 28% increase excluding COVID-19 testing.

The average analyst estimate for Q4 prior to the release of the preliminary financial results was $506.5 million.

For the quarter that ended Dec. 31, the Madison-based diagnostics firm expects screening revenue of $401.8–$402.8 million, an increase of 45% year-over-year.

The firm expects to see Precision Oncology revenue between $142.9–$143.9 million, a decrease of 4%. Anticipated COVID-19 testing revenues of $5.9 million would represent a year-over-year decrease of 87%.

For the full-year of 2022, Exact Sciences expects revenue between $2.082–$2.084 billion, an increase of 18% year-over-year, or 25% excluding COVID-19 testing.